Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) (TA1032)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 January 2025
Relugolix for treating hormone-sensitive prostate cancer (TA995)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 August 2024
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) (TA994)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 August 2024
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 November 2023
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Irreversible electroporation for treating prostate cancer (IPG768)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 5 July 2023
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Transperineal biopsy for diagnosing prostate cancer (DG54)Product type:GuidanceProgramme:Diagnostics guidancePublished: 1 June 2023
MRI fusion biopsy systems for diagnosing prostate cancer (DG53)Product type:GuidanceProgramme:Diagnostics guidancePublished: 24 May 2023
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 May 2023
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG756)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 5 April 2023
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG752)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 7 February 2023
Prostate cancer: diagnosis and management (NG131)Product type:GuidanceProgramme:NICE guidelineLast updated: 15 December 2021Published: 9 May 2019
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2021
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2021
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 August 2021
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 July 2021
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2020
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2019
Padeliporfin for untreated localised prostate cancer (TA546)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 November 2018
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 August 2016Published: 25 May 2016
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published: 27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published: 27 April 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Focal therapy using cryoablation for localised prostate cancer (IPG423)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 April 2012
Transperineal template biopsy and mapping of the prostate (IPG364)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 October 2010
Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy (IPG258)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 April 2008
Laparoscopic radical prostatectomy (IPG193)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 November 2006
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2006
High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer (IPG174)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 May 2006
Cryotherapy as a primary treatment for prostate cancer (IPG145)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 November 2005
Low dose rate brachytherapy for localised prostate cancer (IPG132)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 July 2005
Cryotherapy for recurrent prostate cancer (IPG119)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 May 2005
High-intensity focused ultrasound for prostate cancer (IPG118)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 March 2005
Improving outcomes in urological cancers (CSG2)Product type:GuidanceProgramme:Cancer service guidelinePublished: 19 September 2002
Stockholm3 for prostate cancer screening (MIB303)Product type:AdviceProgramme:Medtech innovation briefingPublished: 9 August 2022
Paige Prostate for prostate cancer (MIB280)Product type:AdviceProgramme:Medtech innovation briefingPublished: 30 November 2021
trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)Product type:AdviceProgramme:Medtech innovation briefingPublished: 13 July 2021
Axumin for functional imaging of prostate cancer recurrence (MIB172)Product type:AdviceProgramme:Medtech innovation briefingPublished: 8 February 2019
Prolaris gene expression assay for assessing long-term risk of prostate cancer progression (MIB65)Product type:AdviceProgramme:Medtech innovation briefingPublished: 24 May 2016
The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)Product type:AdviceProgramme:Medtech innovation briefingPublished: 16 December 2014
Prostate cancer (QS91)Product type:Quality standardLast updated: 30 December 2021Published: 11 June 2015
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016